128 related articles for article (PubMed ID: 33277936)
1. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products.
Wilmot HV; Gray E
Vox Sang; 2021 Jul; 116(6):656-664. PubMed ID: 33277936
[TBL] [Abstract][Full Text] [Related]
2. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
[TBL] [Abstract][Full Text] [Related]
4. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
Behr-Gross ME; Le Tallec D; Sinitskaya N; Milne C; Etscheid M
Pharmeur Bio Sci Notes; 2024; 2024():27-75. PubMed ID: 38533680
[TBL] [Abstract][Full Text] [Related]
5. Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism.
Salge-Bartels U; Heiden M; Groß N; Seitz R
Thromb Res; 2014 Feb; 133(2):244-53. PubMed ID: 24342536
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
Ma L; Sun P; Lin FZ; Diao G; Li CQ
Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
[TBL] [Abstract][Full Text] [Related]
7. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
Kang GB; Huber A; Lee J; Kim MJ; Bang E; Hong J; Park S
Front Cardiovasc Med; 2023; 10():1253177. PubMed ID: 38075963
[TBL] [Abstract][Full Text] [Related]
8. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of residual procoagulants in human intravenous immunoglobulins from 11 Chinese blood fractionation companies.
Ma L; Sun P; Lin F; Diao G; Li C
Thromb Res; 2013 Sep; 132(3):381-5. PubMed ID: 23953595
[TBL] [Abstract][Full Text] [Related]
10. An application of mass spectrometry for quality control of biologicals: Highly sensitive profiling of plasma residuals in human plasma-derived immunoglobulin.
Limonier F; Van Steendam K; Waeterloos G; Brusselmans K; Sneyers M; Deforce D
J Proteomics; 2017 Jan; 152():312-320. PubMed ID: 27894965
[TBL] [Abstract][Full Text] [Related]
11. Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays.
Liang Y; Jackson JW; Woodle SA; Surov SS; Parunov LA; Scott DE; Weinstein M; Lee TK; Ovanesov MV
Res Pract Thromb Haemost; 2021 Jan; 5(1):211-222. PubMed ID: 33537546
[TBL] [Abstract][Full Text] [Related]
12. Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients.
Paszek E; Pociask E; Ząbczyk M; Piórkowski A; Butenas S; Legutko J; Undas A
Atherosclerosis; 2022 Apr; 346():124-132. PubMed ID: 35246318
[TBL] [Abstract][Full Text] [Related]
13. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
[TBL] [Abstract][Full Text] [Related]
14. Amidolytic assay of factor XI in human plasma--significance of kallikrein for the activity measured.
Briseid K; Hoem NO; Johannesen S; Haug K
Thromb Res; 1995 May; 78(3):239-50. PubMed ID: 7631304
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
Waters EK; Hilden I; Sørensen BB; Ezban M; Holm PK
J Thromb Haemost; 2015 Nov; 13(11):2041-52. PubMed ID: 26340413
[TBL] [Abstract][Full Text] [Related]
16. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
Wolberg AS; Kon RH; Monroe DM; Hoffman M
Am J Hematol; 2000 Sep; 65(1):30-4. PubMed ID: 10936860
[TBL] [Abstract][Full Text] [Related]
17. Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events.
Undas A; Slowik A; Gissel M; Mann KG; Butenas S
Thromb Res; 2011 Nov; 128(5):e62-6. PubMed ID: 21820158
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products.
Germishuizen WA; Gyure DC; Stubbings D; Burnouf T
Biologicals; 2014 Sep; 42(5):260-70. PubMed ID: 25096922
[TBL] [Abstract][Full Text] [Related]
19. Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.
Undas A; Slowik A; Gissel M; Mann KG; Butenas S
Eur J Clin Invest; 2012 Feb; 42(2):123-9. PubMed ID: 21707613
[TBL] [Abstract][Full Text] [Related]
20. Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy.
Zabczyk M; Butenas S; Palka I; Nessler J; Undas A
Pol Arch Med Wewn; 2010 Sep; 120(9):334-40. PubMed ID: 20864906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
